Article
Targeting FLT3 to treat leukemia.
Expert opinion on therapeutic targets - 1 Jan 2015
Konig Heiko, Levis Mark
Abstract excerpt
INTRODUCTION: Approximately 23% of acute myeloid leukemia (AML) patients younger than 60 years of age carry a mutation in the transmembrane domain of the FMS-like tyrosine kinase-3 (FLT3) gene (FLT3/internal tandem duplications [ITD]). In normal karyotype AML, the presence of a FLT3/ITD mutation is associated with poor prognosis, as mirrored by a high risk of relapse even after allogeneic stem cell...
Topics
- Animals
- Antineoplastic Agents
- Drug Resistance, Neoplasm
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Protein Kinase Inhibitors
- Recurrence
- fms-Like Tyrosine Kinase 3